Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 1, 2020
Previous Article Next Article

Clickable, acid labile immunosuppressive prodrugs for in vivo targeting

Author affiliations

Abstract

Allotransplantation offers the potential to restore the anatomy and function of injured tissues and organs, but typically requires life-long, systemic administration of immunosuppressive drugs to prevent rejection, which can result in serious complications. Targeting the immunosuppressive drug to the graft favors local tissue concentration versus systemic drug exposure and end-organ toxicity. This could reduce the overall dose and dosing frequency of immunosuppressive drugs, and improve the safety and efficacy of treatment. Here, we developed dibenzocyclooctyne (DBCO)-modified prodrugs of the immunosuppressive drugs tacrolimus, rapamycin and mycophenolic acid, and demonstrated their targeted conjugation both in vitro and in vivo to azido-modified hydrogels via Click chemistry. Such azido-modified hydrogels placed in transplanted tissues enable sustained local release of drugs, and could be repeatedly refilled with systemically administered acid-labile prodrugs after drug exhaustion. Thus, clickable prodrugs with degradable linkers provide new possibilities for graft targeted immunosuppression in the context of allotransplantation.

Graphical abstract: Clickable, acid labile immunosuppressive prodrugs for in vivo targeting

Back to tab navigation

Supplementary files

Article information


Submitted
15 Sep 2019
Accepted
30 Oct 2019
First published
30 Oct 2019

Biomater. Sci., 2020,8, 266-277
Article type
Paper

Clickable, acid labile immunosuppressive prodrugs for in vivo targeting

H. Wang, M. C. Sobral, T. Snyder, Y. Brudno, V. S. Gorantla and D. J. Mooney, Biomater. Sci., 2020, 8, 266
DOI: 10.1039/C9BM01487J

Social activity

Search articles by author

Spotlight

Advertisements